Douglas P. Clark, M.D.

picture of douglas clark

Professor and The Frederick H. Harvey Chair of Pathology

Email: DPClark@salud.unm.edu


Interests:

  • Personalized medicine
  • Oncology related molecular biomarkers
  • Biospecimen science
  • Translating biomarker research into clinical testing and utilization
  • Thyroid cytopathology

Education and Certification Information

Fellowship:
Cytopathology Fellowship
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA
1993-1994

Post-Doctoral Research Fellowship:
Howard Hughes Medical Institute Post-Doctoral Research Fellow
University of Pennsylvania
1991-1993

Post-Doctoral Research Fellowship:
With Dr. Mark I. Greene
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA
1992-1993

Post-Doctoral Research Fellowship:
With Dr. Michael Zasloff
Department of Human Genetics and Molecular Biology
Children’s Hospital of Pennsylvania
Philadelphia, PA
1991-1992

Residency:
Anatomic Pathology Residency
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA
1989-1991

Medical School:
Doctor of Medicine
The Johns Hopkins School of Medicine
Baltimore, MD
1989

Howard Hughes Medical Institute Research Scholar
With Dr. Michael Gottesman
National Cancer Institute
National Institutes of Health
Bethesda, MD
1985-1987

Board Certifications:
Board Certified Anatomic Pathology
American Board of Pathology (1992)

Added qualification in Cytopathology
American Board of Pathology (1994)


Selected Publications:

  • Ball DW, Jin N, Xue P, Bhan S, Ahmed SR, Rosen DM, Schayowitz A, Clark DP, Nelkin BD. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep. 2015 Nov;34(5):2319-24. doi: 10.3892/or.2015.4225. Epub 2015 Aug 26. PMID:26324075

  • Xing M, Alzahrani AS, Carson KA, Viola D, Elsisei R, Bendlova B, Yip L, Mian C, Vianello F, Tutt;e RM, Robenshtok E, Fagin JA, Pexeddu E, Fugazzola L, Czarniecka A, Jarzab B, O’Neill C, Sywak MS, Lam A, Risco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai S, Zeiger MA, Westra WH, Clark DP, Ladenson PW, and Sykorova V: BRAFV600E Mutation Dramatically Increases Papillary Thyroid Cancer-Associated Mortality. JAMA. 2013 Apr 10;309(14):1493-501.

  • Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples using a novel automated platform. PLoS One. 2012;7(12):e52760. doi: 10.1371/journal.pone.0052760. Epub 2012 Dec 28.

  • Tatsas AD, Phelan DF, Gravitt PE, Boitnott JK, Clark DP: Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Path, 2012; 138:223-229.

  • Moore HM, Kelly, AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011 Apr 25;119(2):92-101.

  • Clark DP: Molecular diagnostics on thyroid fine-needle aspirations. The pathway to value Creation. Cancer (Cancer Cytopathol), 2010, 118(1):14-16. (Invited Editorial)

  • Clark DP: Ex vivo biomarkers: Functional tools to guide targeted drug development and therapy. Expert Rev Molec Diagn 2009, 9(8):787-794.

  • Clark DP: Seize the opportunity: Underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer (Cancer Cytopathol), 2009, 117(5):289-297.

Search PubMed:

Douglas P. Clark on PubMed